Background: Clinical Limitations of Existing Single-Omics Analyses and Bottlenecks in Splicing Receptor Data for NSCLC R&D

Conventional, linear genomic screening and static analysis guidelines have failed to fully integrate the dynamic splicing control mechanisms within cancer cells into in silico computational control models. This has created critical data barriers and bottlenecks, hindering the achievement of actual efficacy and prophylactic concentrations for targeted therapeutic agents. In particular, in lung adenocarcinoma R&D, including non-small cell lung cancer (NSCLC), the transcriptional variant behavior induced by the oncogenic driver KRASG12S mutation has been unpredictable using simple DNA sequencing alone. Existing systems have not been able to proactively model cellular dissociation-induced structural collapse noise, false-positive data from high-throughput screening processes, or drug resistance feedback fluxes. This has led to the oversight of a complex dynamic pathway in which the KRASG12S mutation aberrantly generates potential docking sites for the splicing factor U2AF1, leading to non-functional KRAS transcripts and exon skipping. This is a major cause of baseline errors that result in devastating failure rates in the lead optimization stage of targeted drug development.

Discovery: Implementation of a Multidimensional Tensor Splicing Model and Empirical Validation of Single-Cell Resolution Independent Variable Tensor Synchronization

This study implemented a high-performance in silico splicing simulation algorithm to computationally and precisely demonstrate the downstream transcriptomic topological variation curves of genetic mutations by synchronizing independent variable omics data collected at the single-cell level into a multidimensional tensor format. The interaction mechanism between the non-functional exon skipping induced by the KRASG12S mutation and the compensatory U2AF1 co-mutation was dissected in conjunction with a three-dimensional molecular dynamics simulation. The analysis engine fine-tuned the entropic binding free energy between the spliceosome complex and the RNA target sequence and computationally retro-calculated the interaction rate constants, achieving single-nucleotide resolution. This mathematically eliminated the inherent batch effects observed in single-cell experiments, establishing a backbone architecture that dramatically surpasses the limitations of conventional simple genomic analysis models and demonstrates robust molecular integrity.

Establishment of a Model for Coordinating U2AF1-KRASG12S Interaction Pathways and Precisely Stratifying Reversible Homeostatic Gradients

Through the constructed multi-omics matrix engine, a landmark model was established for precisely stratifying patient-specific genetic backgrounds and co-mutation profiles. The rate-limiting steps of splicing control nodes capable of artificially controlling aberrant exon skipping were defined, and the dynamics of downstream pathways of aberrant genomic expression were completely reconstructed by up- and down-regulating the rate-limiting step constants in silico. Therapeutic threshold gradients capable of precisely inducing reversible homeostasis even under anomalous tumor microenvironments and cellular stress were derived, which serve as a precise stratification baseline for companion diagnostics that proactively predict individual genetic-specific therapeutic responses.

Prospects: Establishment of a Programmable Computational Oncology Standard and Implementation of a Next-Generation IND Digital Governance System

As a result, cancer R&D governance is completely reset from a static, post-hoc palliative care system to a programmable computational infrastructure based on AI-driven multidimensional tensor simulations. This computational platform is linked to high-throughput screening genetic gradient correction coefficients within the pipeline development process of global multinational pharmaceutical companies, establishing a computational firewall for zeroing out batch-to-batch variations. Furthermore, it dramatically shortens the time required for clinical approval by ensuring the integrity of cGMP manufacturing production data for clinical authorization and the reliability of pharmacological activity data for Investigational New Drug (IND) applications, and it meets companion diagnostic specifications, positioning it as a core governance asset that overwhelmingly accelerates the timeline for new drug approval.